Pharmacogenetics of oral antidiabetic therapy

Pharmacogenomics. 2018 Apr;19(6):577-587. doi: 10.2217/pgs-2017-0195. Epub 2018 Mar 27.

Abstract

Type 2 diabetes prevalence is still on the rise worldwide. Antidiabetic drugs are widely prescribed to patients with Type 2 diabetes. Most patients start with metformin which is mostly well tolerated. However, a high percentage of patients fail to achieve glycemic control. The effectiveness of metformin as well as most other antidiabetic drugs depends among other factors on interindividual genetic differences that are up to now ignored in the treatment of Type 2 diabetes. Interestingly, many genes influencing the effectiveness of antidiabetic drugs are Type 2 diabetes risk genes making matters worse. Here, we shed light on these interindividual genetic differences.

Keywords: OAD; T2D; Type 2 diabetes; interindividual differences; oral antidiabetic drugs.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / genetics
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / genetics*
  • Metformin / adverse effects
  • Metformin / therapeutic use*
  • Pharmacogenetics*

Substances

  • Hypoglycemic Agents
  • Insulin
  • Metformin